Evaxion Biotech A/S (EVAX) Projected to Post Earnings on Wednesday

Evaxion Biotech A/S (NASDAQ:EVAX) is projected to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Evaxion Biotech A/S to post earnings of ($0.26) per share and revenue of $1.66 million for the quarter.

Evaxion Biotech A/S Stock Performance

Shares of EVAX stock opened at $1.89 on Monday. The firm has a 50 day moving average of $2.59 and a 200-day moving average of $7.69. The company has a market cap of $2.22 million, a price-to-earnings ratio of -1.30 and a beta of -0.25. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 52 week low of $1.70 and a 52 week high of $22.05.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a report on Thursday, February 20th. Lake Street Capital cut their price target on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.